The association between severe deficiency of alpha-1 antitrypsin and early-onset pulmonary emphysema has been known for several decades ([@bib1]). Alpha-1 antitrypsin is encoded by the *SERPINA1* gene, and the most common genetic variants causing deficiency are termed S and Z. The molecular basis of the deficiency is the abnormal folding, polymerization, and retention of the variant proteins in the endoplasmic reticulum of hepatocytes ([@bib2]). The Z variant causes a change in the amino acid sequence (Glu366Lys) and is associated with plasma levels that are 10--15% of the normal M allele, whereas the S variant (Glu288Val) causes a milder deficiency with plasma levels that are 50--60% of normal.

Although the risk for lung disease in ZZ homozygotes is clearly established, the role of additional rare variants of *SERPINA1* has not been adequately explored. This is an important issue, as there are more than 100 other rare variants in the *SERPINA1* gene that have known or predicted deleterious effects ([@bib3]). In addition, whether there is an increased risk for lung disease because of a single copy of the Z allele has been a source of debate in the literature for many years ([@bib4]).

In this issue of the *Journal*, Ortega and colleagues (pp. [540--554](10.1164/rccm.201904-0769OC)) ([@bib5]) present a comprehensive survey of all genetic variants in the *SERPINA1* gene in a large study sample. The authors sequenced the entire *SERPINA1* gene in 2,168 heavy smokers (≥20 pack-years) drawn from the SPIROMICS (Subpopulations and Intermediate Outcome Measures In COPD Study) study. The subjects represent three ethnic groups, and measures of circulating alpha-1 antitrypsin levels were available for 64% of the study participants. This landmark study sheds light on the role of non-Z *SERPINA1* variants and heterozygosity for the Z allele in the pathogenesis of chronic obstructive pulmonary disease.

The sequencing identified 26 variants in the *SERPINA1* gene that cause an amino acid substitution in the alpha-1 antitrypsin protein and one frame-shift mutation that results in complete absence of protein. Several of the rare variants (allele frequency, \<5%) were unique to a particular ethnic group. In the initial analysis, the aggregate effect of rare variants together with the Z and S alleles on measures of lung function and computed tomography scan evidence of emphysema was tested in each ethnic group. In non-Hispanic whites, highly significant additive effects were observed for several lung function and emphysema outcomes. In addition, the level of alpha-1 antitrypsin decreased with the presence of each additional variant. There were no similar associations in the African American and Hispanic groups, but the sample sizes were much smaller, and there were no individuals with two variants in either group.

When considered individually, only the Z allele was associated with any of the outcome measures. As expected, the presence of two copies of the Z allele was associated with large decrements in lung function and increased emphysema. Interestingly, a single copy of the Z allele was also associated with adverse effects on the outcome variables, with values intermediate between those for the normal genotype (MM) and ZZ homozygotes. These data support the results of previous studies ([@bib6], [@bib7]) and confirm that MZ heterozygotes are at increased risk for chronic obstructive pulmonary disease, at least in the presence of heavy smoke exposure.

To achieve a more detailed analysis of the variants, the study participants were categorized into six genotypic groups, separating the effect of the Z allele from the other variants. Using this approach, the authors were able to show that heterozygosity for the Z allele alone was associated with lung function and emphysema in non-Hispanic whites. This result suggests that the disease risk associated with a single copy of the Z allele is not solely a result of compound heterozygotes who have one Z allele and a rare variant in the other copy of *SERPINA1*. Furthermore, heterozygosity for any rare variant associated with low alpha-1 antitrypsin levels (values in the lowest decile) was associated with emphysema independent of the Z and S alleles.

In the African American and Hispanic groups, there were fewer significant associations, which was likely a result of the lower sample sizes. However, in African-Americans, a single base insertion in the 5′ untranslated region of *SERPINA1* was associated with low alpha-1 antitrypsin levels and greater functional small airways disease. *In vitro* data using a reporter gene suggested that the variant alters *SERPINA1* gene regulation, and thus may be the causal variant for this novel clinical association.

The study showed that the rare variants and the Z and S alleles considered in aggregate were associated not only with cross-sectional outcomes but also with accelerated rate of lung function decline during a 3-year-long period. However, there were no associations of individual variants or subgroups of variants with longitudinal outcomes even in non-Hispanic white patients, indicating that a longer follow-up and/or larger sample size may be needed for these analyses.

One of the main strengths of the study was that a large number of non-Hispanic white patients were sequenced across the entire *SERPINA1* coding region. Larger sample sizes for different ethnic groups need to be studied, but the identification of group-specific variants provides a good rationale for performing such studies. Another strength was that the study participants all had significant smoke exposure, thus reducing the potential for lack of penetrance of the variants. The availability of measurements of circulating alpha-1 antitrypsin was an important asset in this study, as it helped guide the interpretation of the genetic association data.

This study illustrates the difficulty in analyzing rare genetic variants: Although there may be significant associations when considered in aggregate (i.e., gene-based burden testing), there are often too few individuals with each variant to test individually with sufficient power. Nevertheless, rare variants are potentially important for the individual patient, and therefore additional large-scale studies such as this are warranted.
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